Research progress on PLK1 in castrate-resistant prostate cancer
10.3969/j.issn.1000-8179.20150436
- VernacularTitle:Polo样激酶1在去势抵抗性前列腺癌中的研究进展
- Author:
Lili WANG
;
Haitao WANG
- Publication Type:Journal Article
- Keywords:
polo-like kinase 1 (PLK1);
castrate-resistant prostate cancer (CRPC);
synthetic lethal;
joint anticancer
- From:
Chinese Journal of Clinical Oncology
2015;(14):720-723
- CountryChina
- Language:Chinese
-
Abstract:
Polo-like kinase 1 (PLK1) is a highly conserved serine/threonine protein kinase that has attracted research attention be-cause it plays a critical role in mitosis regulation. PLK1 is overexpressed in 80%of human tumors, which indicates a poor prognosis in most tumors. PLK1 is one of the most promising targets for antitumor therapy because it is upregulated in castrate-resistant prostate can-cer (CRPC). This review focused on the basic structure and function of PLK1, the relationship between PLK1 and CRPC occurrence and progression, and CRPC treatment by inhibiting PLK1. This study provides a theoretical basis for the targeted molecular therapy of CRPC.
